Additionally, the GLP-1 receptor agonist has shown the ability to counteract the effects of heart failure on action potential duration (APD), AF inducibility, and structural remodeling, as evidenced by a reduction in the volume and fibrosis of the left atrium (LA) [22]. This evidence concerns the gene GLP1R and atrial fibrillation.